Biochem/physiol Actions

Reversible: yes

Primary TargetRAGE

General description

An S100P-derived peptide based competitive antagonist for receptor for advanced glycation end product (RAGE). Shown to disrupt the interaction between RAGE and its ligands, such as S100P, S100A4 and HMGB-1 in binding assays and in multiple cancer cell lines (~2 µM). Also, blocks RAGE-dependent NF-kB activation in MPanc96, MOH and HPAF II tumor cell lines. Systemic administration of RAP also diminishes NF-kB signaling in vivo and significantly reduces glioma tumor growth in murine models.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Arumugam, T., et al. 2012. Clin Cancer Res.18, 4356.

Packaging

Packaged under inert gas

10 mg in Glass bottle

Physical form

Supplied as a trifluoroacetate salt.

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Sequence

Ac-ELKVLMEKEL-NH2

Warning

Toxicity: Standard Handling (A)